JP2007524605A - インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用 - Google Patents

インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用 Download PDF

Info

Publication number
JP2007524605A
JP2007524605A JP2006509702A JP2006509702A JP2007524605A JP 2007524605 A JP2007524605 A JP 2007524605A JP 2006509702 A JP2006509702 A JP 2006509702A JP 2006509702 A JP2006509702 A JP 2006509702A JP 2007524605 A JP2007524605 A JP 2007524605A
Authority
JP
Japan
Prior art keywords
granulation
tissue
antibody
amino acid
integrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006509702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007524605A5 (fr
Inventor
デール イー． ジョンソン，
ウルスラ ジェフリー，
Original Assignee
ピーディーエル バイオファーマ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーディーエル バイオファーマ，インコーポレイティド filed Critical ピーディーエル バイオファーマ，インコーポレイティド
Publication of JP2007524605A publication Critical patent/JP2007524605A/ja
Publication of JP2007524605A5 publication Critical patent/JP2007524605A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006509702A 2003-04-03 2004-04-02 インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用 Withdrawn JP2007524605A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46064203P 2003-04-03 2003-04-03
PCT/US2004/010422 WO2004089988A2 (fr) 2003-04-03 2004-04-02 Procedes de production et utilisation d'anticorps anti-integrine permettant d'inhiber la granulation tissulaire

Publications (2)

Publication Number Publication Date
JP2007524605A true JP2007524605A (ja) 2007-08-30
JP2007524605A5 JP2007524605A5 (fr) 2009-03-12

Family

ID=33159791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509702A Withdrawn JP2007524605A (ja) 2003-04-03 2004-04-02 インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用

Country Status (5)

Country Link
US (2) US20050002930A1 (fr)
EP (1) EP1625165A2 (fr)
JP (1) JP2007524605A (fr)
CA (1) CA2520121A1 (fr)
WO (1) WO2004089988A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521218A (ja) * 2009-03-25 2012-09-13 ジェネンテック， インコーポレイテッド 新規な抗α５β１抗体及びその使用
JP2015503580A (ja) * 2012-01-05 2015-02-02 クラノテク・アクチボラグ 線維症又は線維症関連疾患の治療に使用するための、抗血管新生性のインテグリンα５β１阻害剤であるキノリン化合物
JP2021516961A (ja) * 2018-03-05 2021-07-15 エタブリスモン フランセ ドュ サンＥｔａｂｌｉｓｓｅｍｅｎｔ Ｆｒａｎｃａｉｓ Ｄｕ Ｓａｎｇ 遺伝子組換え単鎖免疫グロブリン

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
KR20070009637A (ko) * 2004-03-24 2007-01-18 피디엘 바이오파르마 인코포레이티드 암 세포 증식을 억제하는 항α5β1 항체의 용도
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
ES2544957T3 (es) 2006-03-21 2015-09-07 Genentech, Inc. Terapia combinada que implica antagonistas alfa5beta1
CA2694644A1 (fr) * 2007-07-27 2009-02-05 Vanitha Ramakrishnan Combinaisons pharmaceutiques
CA2698609A1 (fr) 2007-09-26 2009-04-02 Genentech, Inc. Nouveaux anticorps
BRPI0906387A2 (pt) * 2008-02-05 2015-07-07 Bristol Myers Squibb Co Anticorpos alfa 5 - beta 1 e seus usos
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
EP4269563A3 (fr) * 2010-06-19 2024-01-10 Memorial Sloan-Kettering Cancer Center Anticorps anti-gd2
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (fr) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited Nouvelle composition thérapeutique contenant de l'apomorphine en tant que principe actif
NZ628072A (en) 2012-03-13 2015-08-28 Respivert Ltd Crystalline pi3 kinase inhibitors
JP6482525B2 (ja) 2013-03-15 2019-03-13 メモリアル スローン ケタリング キャンサー センター 高親和性抗ｇｄ２抗体
EP4100062A4 (fr) * 2020-02-05 2024-05-22 Navaux Inc Anticorps anti-hepsine et leurs utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ES2204890T3 (es) * 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
CA2078539C (fr) * 1991-09-18 2005-08-02 Kenya Shitara Procede de fabrication de chimere d'anticorps humain
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
ATE171472T1 (de) * 1992-02-19 1998-10-15 Schering Corp Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP3490443B2 (ja) * 1992-10-29 2004-01-26 ジ・オーストラリアン・ナショナル・ユニバーシティ 血管形成阻害性抗体
US5439699A (en) * 1993-03-11 1995-08-08 Miller Brewing Company Method for preparing colorless clear beer
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
US5846536A (en) * 1996-10-04 1998-12-08 The Regents Of The University Of California Restoration of normal phenotype in cancer cells
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012521218A (ja) * 2009-03-25 2012-09-13 ジェネンテック， インコーポレイテッド 新規な抗α５β１抗体及びその使用
US8962275B2 (en) 2009-03-25 2015-02-24 Genentech, Inc. Anti-α5β1 antibodies and uses thereof
JP2015503580A (ja) * 2012-01-05 2015-02-02 クラノテク・アクチボラグ 線維症又は線維症関連疾患の治療に使用するための、抗血管新生性のインテグリンα５β１阻害剤であるキノリン化合物
JP2021516961A (ja) * 2018-03-05 2021-07-15 エタブリスモン フランセ ドュ サンＥｔａｂｌｉｓｓｅｍｅｎｔ Ｆｒａｎｃａｉｓ Ｄｕ Ｓａｎｇ 遺伝子組換え単鎖免疫グロブリン
JP7497292B2 (ja) 2018-03-05 2024-06-10 エタブリスモン フランセ ドュ サン 遺伝子組換え単鎖免疫グロブリン

Also Published As

Publication number Publication date
WO2004089988A2 (fr) 2004-10-21
EP1625165A2 (fr) 2006-02-15
WO2004089988A3 (fr) 2005-03-17
US20050002930A1 (en) 2005-01-06
CA2520121A1 (fr) 2004-10-21
US20090041785A1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
US20090041785A1 (en) Use of anti-integrin antibodies for reducing scar tissue formation
US11505620B2 (en) Methods of detecting plasma kallikrein
ES2639016T3 (es) Anticuerpos específicos para la forma protofibrilar de proteína beta-amiloide
JP2007524605A5 (fr)
CN104650225B (zh) 用于结合鞘氨醇-1-磷酸的组合物和方法
JP4864175B2 (ja) 発作に関する抗―ｃｄ１８抗体
RU2346701C2 (ru) ХИМЕРНЫЕ И ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ ИНТЕГРИНА α5β1, КОТОРЫЕ МОДУЛИРУЮТ АНГИОГЕНЕЗ
US20060275292A1 (en) Fully human anti-CD3 monoclonal antibodies
JP2002539076A (ja) 新脈管形成抑制のための方法および組成物
US20200000070A1 (en) Mouse model of retinal degeneration
US20110110932A1 (en) Combination treatment for ocular diseases
US6569431B2 (en) Recombinant antibody fragments as autoantibody antagonists
AU2002211771A1 (en) Recombinant antibody fragments as autoantibody antagonists
WO1999013909A1 (fr) Inhibiteurs de neovascularisation corneenne
Pusey et al. Autoimmunity in rapidly progressive glomerulonephritis
JPH08505855A (ja) 炎症を促進する細胞の経内皮移動を調節する方法および関連するその測定方法
TWI508976B (zh) 對β－類澱粉蛋白之基原纖維形式具專一性之抗體

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under section 19 (pct)

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090122

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090622

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090821